2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
Date Title
Oct 16, 2017Printer Friendly VersionTakeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer
Oct 03, 2017Printer Friendly VersionTakeda Announces FDA Approval of ALUNBRIG® (brigatinib) 180 mg Tablets
Oct 03, 2017Printer Friendly VersionSeattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Sep 27, 2017Printer Friendly VersionTakeda to Feature ALUNBRIGTM (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer
Jul 27, 2017Printer Friendly VersionTesaro and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan
Jul 13, 2017Printer Friendly VersionMoving Mountains for Multiple Myeloma Program to Take on Fourth Continent with Climb to Mount Fuji
Jun 26, 2017Printer Friendly VersionTakeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Jun 23, 2017Printer Friendly VersionTakeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting
Jun 07, 2017Printer Friendly VersionTakeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
May 24, 2017Printer Friendly VersionTakeda Showcases Broadened Oncology Portfolio Through Data Presentations at Upcoming Medical Meetings
May 08, 2017Printer Friendly VersionTakeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology
May 02, 2017Printer Friendly VersionMultiple Myeloma Patients and Caregivers Hike Through Grand Canyon to Raise Funds and Awareness for Cancer Research
Apr 28, 2017Printer Friendly VersionTakeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib)
Feb 16, 2017Printer Friendly VersionTakeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
Feb 08, 2017Printer Friendly VersionTakeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research
Feb 06, 2017Printer Friendly VersionPatients Living with Multiple Myeloma Will Climb Mount Kilimanjaro to Raise Funds and Awareness for Cancer Research
Jan 30, 2017Printer Friendly VersionExelixis and Takeda Enter Into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
Jan 19, 2017Printer Friendly VersionTakeda Commences Cash Tender Offer for all Outstanding Shares of ARIAD Pharmaceuticals, Inc.
Jan 11, 2017Printer Friendly VersionMaverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies
Jan 09, 2017Printer Friendly VersionTakeda to Acquire ARIAD Pharmaceuticals, Inc.